Increased efficiency and productivity in rAAV upstream processing

With the approval of multiple gene therapies in recent years, recombinant AAV (rAAV) has been proven to be the most safe and effective delivery vehicle. With the usage of rAAV for clinical and commercial manufacturing for indications in multiple therapeutic areas, the high cost of rAAV production has become a barrier for these therapies to be able to reach a wider population and its application for diseases with fewer number of patients. This review focuses on the current challenges in the upstream manufacturing of rAAVs and recent progress in addressing some of these challenges.